Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BC2059 |
Synonyms | |
Therapy Description |
BC2059 binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BC2059 | BC-2059|BC 2059|Tegatrabetan|Tegavivint | CTNNB1 Inhibitor 26 | Tegavivint (BC2059) binds to beta-catenin (CTNNB1) and interferes with binding to TBL1 and TBLR1, resulting in increased degradation of beta-catenin and potentially leading to increased apoptosis of tumor cells with activated canonical Wnt signaling (PMID: 28500235, PMID: 30793158). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03459469 | Phase I | BC2059 | Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 | Completed | USA | CAN | 0 |